N,1,4,4-Tetramethyl-8-((4-(4-Methylpiperazin-1-Yl)Phenyl)Amino)-4,5-Dihydro-1H-Pyrazolo[4,3-H]Quinazoline-3-Carboxamide N,1,4,4-四甲基-8-((4-(4-甲基哌嗪-1-基)苯基)氨基)-4,5-二氢-1H-吡唑并[4,3-H]喹唑啉-3-甲酰胺
CAS 802539-81-7 MFCD02539817
化学结构图
SMILES: CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2
化学属性
| Mol. Weight | 460.57 |
|---|---|
| Appearance | Solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name Translation | N,1,4,4-四甲基-8-((4-(4-甲基哌嗪-1-基)苯基)氨基)-4,5-二氢-1H-吡唑并[4,3-H]喹唑啉-3-甲酰胺 |
|---|---|
| PubChem Substance ID | 16718576 |
| InChI | InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29) |
| Synonym | N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide PHA 848125 PHA-848125 PHA-848125; PHA848125; PHA 848125; PHA-848125AC; PHA 848125AC; PHA848125AC; Milciclib. PHA-848125AC PHA848125 miliciclib |
| LabNetwork Molecule ID | LN01306105 |
| Chemical Name | N,1,4,4-Tetramethyl-8-((4-(4-Methylpiperazin-1-Yl)Phenyl)Amino)-4,5-Dihydro-1H-Pyrazolo[4,3-H]Quinazoline-3-Carboxamide |
| Formula | C25H32N8O |
| IUPAC Name | N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide |
| InChIKey | RXZMYLDMFYNEIM-UHFFFAOYSA-N |
| Canonical SMILES | O=C(C1=NN(C)C2=C1C(C)(C)CC3=CN=C(NC4=CC=C(N5CCN(C)CC5)C=C4)N=C23)NC |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- Milciclib, also known as PHA-848125 or PHA-848125AC, is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types.
